# DNA-personalized skincare

Skincare formulated against a genetic or epigenetic read of the buyer's skin — a cheek swab typed for ageing-related variants, then matched to actives — sold either as a direct-to-consumer product line or as a white-label engine other beauty brands license.

Source: https://en.bioecon.ru/technology/dna-personalized-skincare/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: EU Cosmetics Regulation 1223/2009 | OECD: Genomics & Bioinformatics | Regulator: FDA (USA), EMA (EU), FTC (USA)]

The premise is narrow and testable: a handful of common variants influence how fast skin
loses collagen, how strongly it responds to UV and oxidative stress, and how well it holds
a barrier — so a product chosen against those variants should beat one chosen off a shelf.
The commercial expression is a cheek swab returned by post, a report on a defined marker
set, and either a bespoke formulation or a mapped regimen. Panel sizes are modest and
disclosed: the SkinDNA laboratory test reads 16 genetic markers across five skin-ageing
categories, Mapmygenome's BeautyMap covers more than 40 skin and hair conditions, and
LifeNome's engine claims to analyse over 20,000 gene-ingredient interactions. Turnaround is
measured in weeks, not days — six to eight weeks on some Australian panels — and pricing
runs from roughly AU$129 for a report-only test to a full DNA analysis bundled with four
personalised products.

The key directions of DNA-personalized skincare are:
1. **Dermatogenomic SNP panels (Genetic skin typing):** a defined set of variants associated with collagen loss, elasticity, pigmentation, sensitivity and oxidative-stress response, read from a mouth swab. SkinDNA's laboratory test examines 16 SNPs across five categories including firmness and elasticity, positioned to flag accelerated collagen loss before it is visible.
2. **Bespoke formulation from a genetic report (Made-to-genotype products):** the report drives an actual product rather than advice. Nomige sells a DNA analysis with a skin report and four personalised products, and runs a reorder path for those products — a subscription shape rather than a one-off test.
3. **White-label personalisation engines (B2B beauty intelligence):** the analytical layer licensed to other brands rather than sold to the consumer. LifeNome's precision-beauty engine covers DNA, microbiome and epigenetic methylation data and is explicitly offered white-labelled, which is how most large beauty brands enter this space.
4. **Epigenetic ageing readouts (Methylation-based testing):** a second measurement axis that changes over time, unlike genotype. Muhdo built its epigenetic supplement range on data from 70,000 individuals and publishes gene-level skin-health content, extending the model from fixed variants to modifiable methylation state.

### Sectoral value chain

```
[Swab kit] ──> [Sample collection] ──> [Genotyping/methylation] ──> [Report]
                                                 │
                                       (gene-ingredient rules)
                                                 │
                                                 ▼
[Reorder / retest] <─── [Formulation or regimen] <┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Panel design** | A marker set is selected from published skin-genetics associations and fixed as the product's analytical scope. | **In:** dermatogenomics literature, candidate SNPs, methylation sites.<br>**Out:** a disclosed panel of defined size and category structure. |
| **Kit & sampling** | A buccal swab kit reaches the consumer with collection instructions and a return path to the laboratory. | **In:** swab kit, consumer instructions, prepaid return.<br>**Out:** a labelled sample with usable DNA yield. |
| **Laboratory analysis** | The sample is genotyped for the panel, or assayed for methylation, in a contracted or in-house laboratory. | **In:** buccal sample, genotyping array or methylation assay.<br>**Out:** raw variant or methylation calls. |
| **Interpretation** | Calls are translated into category scores — firmness, pigmentation, sensitivity — against the vendor's rule set. | **In:** variant calls, association rules, lifestyle questionnaire.<br>**Out:** a per-category skin report. |
| **Formulation or regimen** | The report drives either a bespoke formulation or a mapped selection from an existing range. | **In:** category scores, active-ingredient library, formulation constraints.<br>**Out:** personalised product set or recommended regimen. |
| **Reorder & retest** | The relationship continues through product replenishment and, for epigenetic tests, periodic retesting. | **In:** usage cadence, methylation drift for epigenetic products.<br>**Out:** repeat revenue and an updated recommendation. |

Cross-cutting technologies of the sector:
- **Buccal-swab sample logistics (At-home DNA collection):** mouth-swab kits and postal return, the same consumer-genomics infrastructure that made ancestry testing a mass product, reused for a cosmetic endpoint.
- **Gene-ingredient rule engines (Ingredient matching):** the mapping layer between a variant call and an active — the actual intellectual property in this category, and where LifeNome's claimed 20,000-plus interaction set sits.
- **Methylation clocks for skin (Epigenetic readout):** assays that measure a modifiable biological state rather than a fixed genotype, allowing a retest to show change and turning a one-off purchase into a monitored one.

---

## US

The US pattern is business-to-business: the technology is sold to beauty brands as an
engine rather than to consumers as a brand, which is what lets a small team reach a mass
market.

### White-label precision-beauty engines, multi-omic personalisation, small teams behind large brands
- **LifeNome:** founded in 2016 and headquartered in New York with a team in the single digits and $5.1 million raised across two rounds, it sells a precision-beauty engine covering DNA, microbiome and epigenetic methylation, analysing gene-ingredient interactions and offering white-labelled reports that partner brands ship under their own name.
- **Multi-omic framing:** the US vendors have largely moved past genotype alone, folding microbiome and methylation data into the same recommendation, which broadens the claim surface and also the evidentiary burden.
- **Claim discipline:** because the endpoint is cosmetic rather than medical, marketing sits under FTC substantiation rules rather than a regulatory approval process, which is the constraint that shapes how these products describe themselves.

---

## CN

China is a large personalised-cosmetics market, but no domestic DNA-skincare vendor cleared
confirmation on this screen, so the region is described rather than tabled.

### Personalisation without genotyping, regulatory caution on genetic data, unconfirmed vendor set
- **Different personalisation route:** the mainstream Chinese approach to bespoke skincare leans on instrument-based skin analysis and AI imaging in retail settings rather than on a mailed DNA sample, so the buyer journey does not pass through a genotyping laboratory.
- **Genetic-data governance:** human genetic resources are tightly regulated in China, which raises the compliance cost of a consumer service built on collecting and processing DNA for a cosmetic purpose.
- **Screening limit:** searches for 皮肤基因检测 and 定制护肤 returned no vendor that could be confirmed as a merchant of a DNA-based skincare product, so no Chinese row is claimed here.

---

## EU

Europe is where the direct-to-consumer product form is strongest: a founder-led brand
selling a genetic analysis bundled with the creams it prescribes.

### Founder-led DNA cosmetics brands, bundled analysis and product, epigenetics as the adjacent market
- **Nomige:** a Belgian brand founded by Dr Barbara Geusens on dermatogenomics research, selling a DNA analysis with a skin report and four personalised products, plus a day-cream range addressed to specific concerns — stress protection, barrier repair, redness, pigmentation — and a reorder path for the personalised formulations.
- **Muhdo:** a UK epigenetics company whose supplement range is informed by data from 70,000 individuals and which publishes gene-level skin-health material, representing the methylation-based rather than genotype-based end of the same market.
- **Cosmetics framing:** under Regulation 1223/2009 these remain cosmetic products, so the genetic report is a selection aid and not a therapeutic claim — a boundary the credible vendors are careful to keep.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Nomige** | 🇧🇪 Belgium | *DNA analysis plus personalised products* | Dermatogenomics-led bespoke formulation | commercial |
| **LifeNome** | 🇺🇸 USA | *Precision-beauty engine* | White-label DNA, microbiome and methylation | commercial |
| **SkinDNA** | 🇦🇺 Australia | *Skin DNA laboratory test* | 16 SNPs across five ageing categories | commercial |
| **Mapmygenome** | 🇮🇳 India | *BeautyMap* | Skin and hair panel, 40+ conditions | commercial |
| **Muhdo** | 🇬🇧 United Kingdom | *Epigenetic testing and supplements* | Methylation readout, 70,000-person dataset | commercial |

---

## Tech stack and innovations

Three layers stack up, and only the middle one is genuinely hard: collection is commodity,
laboratory work is contracted, and the interpretation rules are the product.

1. **Panel selection and disclosure (SNP panel design):**
   - Panels are deliberately small and named — 16 markers in five categories on the SkinDNA test, 40-plus conditions on Mapmygenome's BeautyMap — because a defined scope is easier to substantiate than an open-ended genomic claim.
   - Categories map to concerns a buyer already recognises: firmness and elasticity, pigmentation, sensitivity, oxidative stress, so the report lands as advice rather than as data.
2. **Gene-ingredient rule engines (Interpretation layer):**
   - This is where the differentiation lives. LifeNome's engine is built around gene-ingredient interactions at a claimed scale of more than 20,000, which is the asset a licensing beauty brand is actually buying.
   - The same layer determines whether the output is a bespoke formulation, as at Nomige, or a mapped selection from an existing catalogue — a formulation decision as much as an analytical one.
3. **Methylation as a second axis (Epigenetic testing):**
   - Genotype does not change, so a genotype-based product can only be sold once; methylation does change, which supports retesting and a monitoring relationship. Muhdo built its range on that distinction with a 70,000-individual dataset behind it.
   - It also shifts the claim from predisposition to current state, which is a stronger consumer proposition and a correspondingly higher evidentiary bar.

---

## Value chains and production pipelines

### Industrial pipeline for genotype-guided cosmetic formulation (EU Cosmetics Regulation 1223/2009)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Panel definition       │ ───> │ 2. Swab kit & collection  │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Report generation      │ <─── │ 3. Laboratory genotyping  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Formulation or regimen │ ───> │ 6. Reorder & retest       │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Panel definition
A marker set is fixed from published skin-genetics associations and grouped into consumer-legible categories — the SkinDNA panel's five categories over 16 SNPs is typical of the scale. Fixing the panel also fixes the claim, which is why vendors publish the count.

#### Stage 2: Swab kit & collection
A buccal swab kit ships with instructions and a prepaid return. The step is commodity consumer-genomics logistics, and its failure mode is a low-yield or contaminated sample rather than anything analytical.

#### Stage 3: Laboratory genotyping
The sample is typed for the panel or assayed for methylation, usually in a contracted laboratory. Turnaround is the visible cost: six to eight weeks is quoted on some Australian skin panels, an eternity by the standards of consumer beauty.

#### Stage 4: Report generation
Variant calls become per-category scores against the vendor's rule set, often combined with a lifestyle questionnaire. This is where a genotype becomes a recommendation, and where two vendors reading the same sample can legitimately differ.

#### Stage 5: Formulation or regimen
The report either drives a bespoke formulation — Nomige's model, a DNA analysis bundled with four personalised products — or maps to items in an existing range, which is the lower-cost route most licensing brands take.

#### Stage 6: Reorder & retest
Genotype-based products monetise through replenishment of the personalised formulation; epigenetic products add periodic retesting, since methylation state moves and a second measurement can show it.